<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00701896</url>
  </required_header>
  <id_info>
    <org_study_id>2007H0173</org_study_id>
    <secondary_id>R01HL090313</secondary_id>
    <nct_id>NCT00701896</nct_id>
  </id_info>
  <brief_title>Smoking Cessation Using Motivational Therapy and Varenicline</brief_title>
  <official_title>Smoking Cessation and the Natural History of HIV-Associated Emphysema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Philip Diaz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Ohio State University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      People that are infected with HIV appear to be especially susceptible to the adverse effects&#xD;
      of cigarette smoking. The purpose of this study is to determine if quitting smoking by using&#xD;
      a specialized smoking cessation treatment can prevent one from developing accelerated lung&#xD;
      damage, particularly emphysema.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      HIV-infected smokers are at increased risk for life-threatening diseases, such as pneumonia.&#xD;
      To date, very little is known about the tobacco consumption characteristics of this at-risk&#xD;
      population of smokers, but it has been well documented that they are at high risk for&#xD;
      smoking-related co-morbidities. In addition, few effective cessation strategies have been&#xD;
      described in HIV-infected populations. A specialized smoking cessation that combines&#xD;
      recommendations from an existing scientifically-valid clinical guideline with Motivational&#xD;
      Interviewing a new pharmacotherapeutic agent, may be an effective mechanism to apply to this&#xD;
      vulnerable population of smokers. This initial, efficacy investigation has the potential to&#xD;
      guide future treatment and research pertaining to tobacco cessation, respiratory illness and&#xD;
      HIV.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 3, 2008</start_date>
  <completion_date type="Actual">June 20, 2013</completion_date>
  <primary_completion_date type="Actual">April 20, 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To Determine the Safety of Varenicline in PLWH Who Smoke</measure>
    <time_frame>3 months</time_frame>
    <description>To determine the safety and tolerability of varenicline compared to nicotine replacement</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To Determine the Efficacy of Varenicline for Smoking Cessation Among PLWH Who Smoke</measure>
    <time_frame>12 months</time_frame>
    <description>To compare biochemically confirmed tobacco abstinence rates among smokers living with HIV treated with nicotine replacement vs varenicline</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">294</enrollment>
  <condition>Smoking</condition>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Healthy Control - Non-smoking</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Healthy Control arm with 51 subjects who are HIV negative and do not smoke</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Control - Smoker</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Healthy Control arm, includes 50 subjects who are HIV negative and are smokers.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HIV Smoking Cessation Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Includes up to 365 subjects who are HIV positive and initiate smoking cessation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Motivational Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Includes up to 100 subjects who are HIV positive, do not wish to quit smoking but are willing to undergo one-on-one Motivational Intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Varenicline tartrate</intervention_name>
    <description>1 mMg tablet form; daily during week 1 (pre-quit week) followed by 1 mg twice daily for weeks 2-12.</description>
    <arm_group_label>HIV Smoking Cessation Arm</arm_group_label>
    <other_name>Chantix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotine Replacement Therapy</intervention_name>
    <description>Nicotine gum and nicotine patch</description>
    <arm_group_label>HIV Smoking Cessation Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Biological Control</intervention_name>
    <description>No treatment intervention only information and procedures.</description>
    <arm_group_label>Healthy Control - Non-smoking</arm_group_label>
    <arm_group_label>Healthy Control - Smoker</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Motivational Interview</intervention_name>
    <description>60 minute one-on-one Interview</description>
    <arm_group_label>Motivational Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 18 years of age and older;&#xD;
&#xD;
          2. diagnosis of HIV;&#xD;
&#xD;
          3. self-reported smoking on a daily basis;&#xD;
&#xD;
          4. provide informed written consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. persons with active psychosis or impaired mental status as judged by the clinic staff&#xD;
             and confirmed with a Mini-Mental Status Exam)&#xD;
&#xD;
          2. unable to understand spoken English&#xD;
&#xD;
          3. age less than 18 years.&#xD;
&#xD;
          4. pregnant women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philip T. Diaz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>June 17, 2008</study_first_submitted>
  <study_first_submitted_qc>June 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 19, 2008</study_first_posted>
  <results_first_submitted>December 18, 2020</results_first_submitted>
  <results_first_submitted_qc>December 18, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 15, 2021</results_first_posted>
  <last_update_submitted>December 18, 2020</last_update_submitted>
  <last_update_submitted_qc>December 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ohio State University</investigator_affiliation>
    <investigator_full_name>Philip Diaz</investigator_full_name>
    <investigator_title>Director, Pulmonary Rehabilitation Services; Medical Director, Respiratory Therapy; Associate Director, General Clinical Research Center</investigator_title>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Positive</keyword>
  <keyword>Smokers</keyword>
  <keyword>Varenicline</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
    <mesh_term>Varenicline</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Nicotine Replacement Plus Motivational Interviewing</title>
          <description>PLWH who smoke&#xD;
12 week intervention with telephone counseling plus:&#xD;
Nicotine Replacement Therapy: Nicotine gum (4 mg ad lib) and nicotine patch (21 mg)</description>
        </group>
        <group group_id="P2">
          <title>Varenicline Plus Motivational Interviewing</title>
          <description>PLWH who smoke&#xD;
12 week intervention with telephone counseling plus:&#xD;
Varenicline tartrate: 0.5 mg daily days 1-3; 0.5 mg twice daily days 4-7; then 1.0 mg twice daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="143">Includes those eligible but declined to participate</participants>
                <participants group_id="P2" count="151">Includes those eligible but declined to participate</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="110"/>
                <participants group_id="P2" count="118"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Nicotine Replacement Plus Motivational Interviewing</title>
          <description>PLWH who smoke&#xD;
12 week intervention with telephone counseling plus:&#xD;
Nicotine Replacement Therapy: Nicotine gum (4 mg ad lib) and nicotine patch (21 mg)</description>
        </group>
        <group group_id="B2">
          <title>Varenicline Plus Motivational Interviewing</title>
          <description>PLWH who smoke&#xD;
12 week intervention with telephone counseling plus:&#xD;
Varenicline tartrate: 0.5 mg daily days 1-3; 0.5 mg twice daily days 4-7; then 1.0 mg twice daily</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="110"/>
            <count group_id="B2" value="118"/>
            <count group_id="B3" value="228"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="110"/>
                    <measurement group_id="B2" value="118"/>
                    <measurement group_id="B3" value="228"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.7" lower_limit="20" upper_limit="63"/>
                    <measurement group_id="B2" value="42.8" lower_limit="25" upper_limit="59"/>
                    <measurement group_id="B3" value="42.8" lower_limit="20" upper_limit="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="93"/>
                    <measurement group_id="B2" value="101"/>
                    <measurement group_id="B3" value="194"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="110"/>
                    <measurement group_id="B2" value="117"/>
                    <measurement group_id="B3" value="227"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="92"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="72"/>
                    <measurement group_id="B3" value="127"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="110"/>
                    <measurement group_id="B2" value="118"/>
                    <measurement group_id="B3" value="228"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>To Determine the Safety of Varenicline in PLWH Who Smoke</title>
        <description>To determine the safety and tolerability of varenicline compared to nicotine replacement</description>
        <time_frame>3 months</time_frame>
        <population>Three-month abstinence rates among participants who received NRT were compared with those who received varenicline. Although some participants stopped taking the pharmacotherapy, or switched from varenicline to NRT, for the analysis , they were kept in their initial group. Because treatment assignment was not random, inverse probability of treatment weighting (IPTW) adjustment was performed. A propensity score was estimated as the probability of receiving varenicline, given measured covariates</population>
        <group_list>
          <group group_id="O1">
            <title>Nicotine Replacement Plus Motivational Interviewing</title>
            <description>PLWH who smoke&#xD;
12 week intervention with telephone counseling plus:&#xD;
Nicotine Replacement Therapy: Nicotine gum (4 mg ad lib) and nicotine patch (21 mg)</description>
          </group>
          <group group_id="O2">
            <title>Varenicline Plus Motivational Interviewing</title>
            <description>PLWH who smoke&#xD;
12 week intervention with telephone counseling plus:&#xD;
Varenicline tartrate: 0.5 mg daily days 1-3; 0.5 mg twice daily days 4-7; then 1.0 mg twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>To Determine the Safety of Varenicline in PLWH Who Smoke</title>
          <description>To determine the safety and tolerability of varenicline compared to nicotine replacement</description>
          <population>Three-month abstinence rates among participants who received NRT were compared with those who received varenicline. Although some participants stopped taking the pharmacotherapy, or switched from varenicline to NRT, for the analysis , they were kept in their initial group. Because treatment assignment was not random, inverse probability of treatment weighting (IPTW) adjustment was performed. A propensity score was estimated as the probability of receiving varenicline, given measured covariates</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="110"/>
                <count group_id="O2" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Insomnia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vivid dreams</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Suicidal ideation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Depressed mood</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Skin rash</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Determine the Efficacy of Varenicline for Smoking Cessation Among PLWH Who Smoke</title>
        <description>To compare biochemically confirmed tobacco abstinence rates among smokers living with HIV treated with nicotine replacement vs varenicline</description>
        <time_frame>12 months</time_frame>
        <population>Abstinence rates among participants who received NRT were compared with those who received varenicline. Although some participants stopped taking the pharmacotherapy, or switched from varenicline to NRT, for the analysis , they were kept in their initial group. Because treatment assignment was not random, inverse probability of treatment weighting (IPTW) adjustment was performed. A propensity score was estimated as the probability of receiving varenicline, given measured covariates</population>
        <group_list>
          <group group_id="O1">
            <title>Nicotine Replacement Plus Motivational Interviewing</title>
            <description>PLWH who smoke&#xD;
12 week intervention with telephone counseling plus:&#xD;
Nicotine Replacement Therapy: Nicotine gum (4 mg ad lib) and nicotine patch (21 mg)</description>
          </group>
          <group group_id="O2">
            <title>Varenicline Plus Motivational Interviewing</title>
            <description>PLWH who smoke&#xD;
12 week intervention with telephone counseling plus:&#xD;
Varenicline tartrate: 0.5 mg daily days 1-3; 0.5 mg twice daily days 4-7; then 1.0 mg twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>To Determine the Efficacy of Varenicline for Smoking Cessation Among PLWH Who Smoke</title>
          <description>To compare biochemically confirmed tobacco abstinence rates among smokers living with HIV treated with nicotine replacement vs varenicline</description>
          <population>Abstinence rates among participants who received NRT were compared with those who received varenicline. Although some participants stopped taking the pharmacotherapy, or switched from varenicline to NRT, for the analysis , they were kept in their initial group. Because treatment assignment was not random, inverse probability of treatment weighting (IPTW) adjustment was performed. A propensity score was estimated as the probability of receiving varenicline, given measured covariates</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="110"/>
                <count group_id="O2" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>3 month biochemically confirmed abstinence rate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 month biochemically confirmed abstinence rate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 month biochemically confirmed abstinence rate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Nicotine Replacement Plus Motivational Interviewing</title>
          <description>PLWH who smoke&#xD;
12 week intervention with telephone counseling plus:&#xD;
Nicotine Replacement Therapy: Nicotine gum (4 mg ad lib) and nicotine patch (21 mg)</description>
        </group>
        <group group_id="E2">
          <title>Varenicline Plus Motivational Interviewing</title>
          <description>PLWH who smoke&#xD;
12 week intervention with telephone counseling plus:&#xD;
Varenicline tartrate: 0.5 mg daily days 1-3; 0.5 mg twice daily days 4-7; then 1.0 mg twice daily</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicidal Ideation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="94" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Vivid dreams</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>agitation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin Rash</sub_title>
                <description>Skin rash</description>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="110"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Skin redness</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="110"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Philip Diaz</name_or_title>
      <organization>Ohio State University</organization>
      <phone>6142934925</phone>
      <email>diaz.3@osu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

